Product Description
Mechanisms of Action: Gram+ Bacteria Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dong Wha
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Chronic Obstructive Pulmonary Disease
Phase 2: Pneumonia
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Bacteriocide | P1 |
Completed |
Healthy Volunteers |
2014-08-01 |
|
DW224-III-3 | P3 |
Completed |
Chronic Obstructive Pulmonary Disease |
2014-01-01 |
|
PB-101-200 | P2 |
Terminated |
Pneumonia |
2012-04-01 |